This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 50/4/686    most recent HYPERTENSIONAHA.107.092098v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, Z. Articles by Pollitt, N. S. Search for Related Content PubMed PubMed Citation Articles by Li, Z. Articles by Pollitt, N. S. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information High Blood Pressure High Risk Pregnancy Related Collections Other hypertension Other etiology Endothelium/vascular type/nitric oxide Other Treatment Angiogenesis Animal models of human disease Hypertension - basic studies

(Hypertension. 2007;50:686.)
© 2007 American Heart Association, Inc.

Original Articles

Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia

Zhihe Li; Ying Zhang; Jing Ying Ma; Ann M. Kapoun; Qiming Shao; Irene Kerr; Andrew Lam; Gilbert O’Young; Frederick Sannajust; Peter Stathis; George Schreiner; S. Ananth Karumanchi; Andrew A. Protter; N. Stephen Pollitt

From Scios Inc. (Z.L., Y.Z., J.Y.M., A.M.K., Q.S., I.K., A.L., G.O., F.S., P.S., G.S., A.A.P., N.S.P.), Fremont, Calif; and Beth Israel Deaconess Medical Center (S.A.K.), Harvard Medical School, Boston, Mass.

Correspondence to N. Stephen Pollitt, 1037 Campbell Ave, Los Altos, CA 94024. E-mail steve{at}pollitts.net

Inhibitors of angiogenic factors are known to be upregulated, and their levels increase in the maternal circulation before the onset of preeclampsia. We reproduced a previously characterized model of preeclampsia by adenoviral overexpression of the soluble vascular endothelial growth factor (VEGF) receptor sFlt-1 (also referred to as sVEGFR-1) in pregnant and nonpregnant Sprague-Dawley rats. Animals were treated with VEGF121 at 0, 100, 200, or 400 µg/kg once or twice daily (n=8 per group; 64 total) and compared with normal control animals (n=4 per group) by examination of systolic blood pressure, urinary albumin and creatinine, renal histopathology, and glomerular gene expression profiling. sFlt-1 expression induced hypertension with proteinuria and glomerular endotheliosis and significant changes in gene expression. VEGF121 treatment alleviated these symptoms and reversed 125 of 268 sFlt-1–induced changes in gene expression. VEGF121 had beneficial effects in this rat model of preeclampsia without apparent harm to the fetus. Further study of VEGF121 as a potential therapeutic agent for preeclampsia is warranted.

Key Words: VEGF121 • preeclampsia • sFlt-1 • blood pressure • glomerular endotheliosis • sVEGFR-1

This article has been cited by other articles:

				B. D. LaMarca, J. Gilbert, and J. P. Granger Recent Progress Toward the Understanding of the Pathophysiology of Hypertension During Preeclampsia Hypertension, April 1, 2008; 51(4): 982 - 988. [Full Text] [PDF]

				V. Eremina, J. A. Jefferson, J. Kowalewska, H. Hochster, M. Haas, J. Weisstuch, C. Richardson, J. B. Kopp, M. G. Kabir, P. H. Backx, et al. VEGF Inhibition and Renal Thrombotic Microangiopathy N. Engl. J. Med., March 13, 2008; 358(11): 1129 - 1136. [Abstract] [Full Text] [PDF]

				J. S. Gilbert, M. J. Ryan, B. B. LaMarca, M. Sedeek, S. R. Murphy, and J. P. Granger Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H541 - H550. [Abstract] [Full Text] [PDF]